Marinus (MRNS) - P/E Multiple

Marinus Pharma - graphic logo of issuer MRNS

The market trend for Marinus Pharmaceuticals (MRNS) demonstrates a value of -0.20, confirming the market position of this epilepsy therapy developer. Patent protections for formulas and the complexities of neurosteroid synthesis block the entry of cheap generics. Business revenues are based on the demand for ganaxolone and the expansion of its application. However, international conflicts and sanctions are hindering the logistics of biomaterials, complicating the certification of new products.

Marinus Pharmaceuticals, Inc. (MRNS) - P/E Multiple from 07/04/2022 to 02/22/2025

Analytical breakdowns for Marinus Pharma (MRNS)

Comprehensive company analysis:Marinus Pharmaceuticals
Product sample of Marinus

The P/E ratio reflects the relationship between the market value of Marinus Pharmaceuticals (MRNS) and its net income. This coefficient determines the investment payback period through actual cash flows. By analyzing the company's P/E range, an investor identifies the degree of asset overvaluation relative to its yield. The multiplier's dynamics depend directly on the sales volumes of epilepsy treatment drugs. The stability of this metric confirms the effectiveness of insurance coverage and hospital procurement of innovative medicines.

Competing companies

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|ALZN - P/E Multiple|Cyclerion (CYCN) - Price to Earnings Ratio|Protagenic (PTIX) - P/E Multiple|Price to Earnings Ratio Pasithea|Price to Earnings Multiple CRGT (Cortigent)|Price to Earnings Ratio Avenue Therapeutics (ATXI)|BCLI - Market Cap to Earnings|P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Price to Earnings Ratio|ELYM: Price to Earnings Ratio|Business Payback Period Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple